Nvidia Acquires Predictive AI Startup Kumo for Over $400 Million
According to monitoring by Beating, Nvidia has acquired Kumo AI, a predictive artificial intelligence startup founded five years ago, for a reported amount exceeding $400 million. The acquisition aims to leverage Kumo's predictive large models to provide predictive analytics services based on structured data for enterprise clients. Kumo's three co-founders, including former Pinterest CTO Vanja Josifovski, Stanford professor Jure Leskovec, and former LinkedIn AI head Hema Raghavan, will join Nvidia in May 2026. Enterprise structured data consists of multiple interrelated data tables, which are generally difficult for large language models to parse directly. Kumo combines graph machine learning technology with synthetic data generated in simulated business environments to train proprietary large models capable of predicting customer churn rates or payment defaults, thus enabling intelligent predictions on enterprise data warehouses. Nvidia may integrate Kumo's technology into its AI Foundry software services to assist businesses in combining private data with domain knowledge to customize proprietary models tailored to their business scenarios. In April 2026, Kumo released its latest predictive model, KumoRFM-2. Currently, Kumo's partners and clients include companies such as DoorDash, Reddit, Databricks, and Snowflake. Compared to its $20 billion acquisition of Groq's inference chip technology at the end of 2025, Nvidia shows a preference for smaller to medium-sized transactions in its mergers and acquisitions. According to securities regulatory filings, Nvidia's cumulative acquisition spending over the past five years is approximately $3 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
